ArticleInternational journal of nanomedicine2019
Strategic approach to developing a self-microemulsifying drug delivery system to enhance antiplatelet activity and bioavailability of ticagrelor.
Article in International journal of nanomedicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- The Role of In Vitro Model Complexity in Lipid-Based Formulation Screening: A Case Study with Ticagrelor.ACS omega · 2026Article
- Boosting luteolin bioavailability via P-glycoprotein efflux inhibition: a self-microemulsifying drug delivery systems.Journal of advanced research · 2026Article
- Design, Optimization and Pharmacokinetic Profiling of BCS Class II Drug Loaded Oral Self Nanoemulsifying System.AAPS PharmSciTech · 2026Article
- Fenofibrate microemulsion eyedrops for treating nitrogen mustard induced corneal injury.Journal of controlled release : official journal of the Controlled Release Society · 2026Article
- Ticagrelor-Loaded Phospholipid-Polyoxyethylene Hybrid Nanocarriers: Enhanced Solubility and Efficacy Against SARS-CoV-2.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Bioavailability Enhancement and Polymorphic Stabilization of One BCS Class IV Metastable Drug Through Novel Formulation Approach.Turkish journal of pharmaceutical sciences · 2025Article
- Synthesis, characterization andNanoscale advances · 2025Article
- Article
- Bioanalytical method development,Frontiers in medical technology · 2025Article
- Crosslinked PVA-ACS omega · 2024Article
- Preparation and Evaluation of a Self-Emulsifying Drug Delivery System for Improving the Solubility and Permeability of Ticagrelor.ACS omega · 2024Article
- Celecoxib Oral Solution and the Benefits of Self-Microemulsifying Drug Delivery Systems (SMEDDS) Technology: A Narrative Review.Pain and therapy · 2023Review
- Application of Design of Experiments in the Development of Self-Microemulsifying Drug Delivery Systems.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Optimization of a Cefuroxime Axetil-Loaded Liquid Self-Nanoemulsifying Drug Delivery System: Enhanced Solubility, Dissolution and Caco-2 Cell Uptake.Pharmaceutics · 2022Article
- Synthesis and evaluation of chitosan based controlled release nanoparticles for the delivery of ticagrelor.Designed monomers and polymers · 2022Article
- pH-Responsive Nanocomposite Based Hydrogels for the Controlled Delivery of Ticagrelor; In Vitro and In Vivo Approaches.International journal of nanomedicine · 2021Article
- Drug Repositioning For Allosteric Modulation of VIP and PACAP Receptors.Frontiers in endocrinology · 2021Article
- Development and Evaluation of Docetaxel-Phospholipid Complex Loaded Self-Microemulsifying Drug Delivery System: Optimization and In Vitro/Ex Vivo Studies.Pharmaceutics · 2020Article
- Article
- Development of an Orally Bioavailable Isoliquiritigenin Self-Nanoemulsifying Drug Delivery System to Effectively Treat Ovalbumin-Induced Asthma.International journal of nanomedicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTicagrelor (TCG) is used to inhibit platelet aggregation in patients with acute coronary syndrome, but its poor solubility and low bioavailability limit its in vivo efficacy. The purpose of this study was to manufacture an optimized TCG-loaded self-microemulsifying drug delivery system (SMEDDS) to enhance the oral bioavailability and antiplatelet activity of TCG. MATERIALS AND
methodsSolubility and emulsification tests were conducted to determine the most suitable oils, surfactants, and cosurfactants. Scheffé's mixture design was applied to optimize the percentage of each component applied in the SMEDDS formulation to achieve optimal physical characteristics, ie, high solubility of TCG in SMEDDS, small droplet size, low precipitation, and high transmittance.
resultsThe optimized TCG-loaded SMEDDS (TCG-SM) formulation composed of 10.0% Capmul MCM (oil), 53.8% Cremophor EL (surfactant), and 36.2% Transcutol P (cosurfactant) significantly improving the dissolution of TCG in various media compared with TCG in Brilinta
conclusionThese results suggest that the developed TCG-SM could be successfully used as an efficient method to achieve the enhanced antiplatelet activity and bioavailability of TCG.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.